Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S R Weiss

Showing results (211-220 of 216) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 216 results.
JAMA|January 10, 1996
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemiaR G Bakker-Arkema, M H Davidson, R J Goldstein, et al.
Pharmacoeconomics|June 6, 1998
The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatinM J Koren, D G Smith, D B Hunninghake, et al.
Diabetes Care|August 14, 1998
Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind studyP A Hollander, S C Elbein, I B Hirsch, et al.
The American Journal of Cardiology|January 1, 1997
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/dayM H Davidson, E A Stein, C A Dujovne, et al.
The Journal of Clinical Endocrinology and Metabolism|February 26, 2000
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study GroupH G Bone, S L Greenspan, C McKeever, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|February 24, 2001
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemiaM H Davidson, E A Stein, D B Hunninghake, et al.
Pageof 22

Showing results (211-220 of 216) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 216 results.
JAMA|January 10, 1996
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemiaR G Bakker-Arkema, M H Davidson, R J Goldstein, et al.
Pharmacoeconomics|June 6, 1998
The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatinM J Koren, D G Smith, D B Hunninghake, et al.
Diabetes Care|August 14, 1998
Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind studyP A Hollander, S C Elbein, I B Hirsch, et al.
The American Journal of Cardiology|January 1, 1997
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/dayM H Davidson, E A Stein, C A Dujovne, et al.
The Journal of Clinical Endocrinology and Metabolism|February 26, 2000
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study GroupH G Bone, S L Greenspan, C McKeever, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|February 24, 2001
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemiaM H Davidson, E A Stein, D B Hunninghake, et al.
Pageof 22